地拉罗司的效果如何？

What kind of medicine does Deferasirox treat? Deferasirox (Deferasirox) was developed by Novartis. Indian cipla pharmaceutical company also has a generic version of Deferasirox (Deferasirox). Deferasirox is currently the only oral iron chelator. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. So, how effective is Deferasirox?

To analyze the clinical efficacy and adverse reactions of the new iron chelator Deferasirox in the treatment of secondary iron overload in myelodysplastic syndrome (MDS). 

This study retrospectively analyzed the clinical data of patients with MDS secondary iron overload who were treated with the new iron chelator Deferasirox at the General Hospital of the People's Liberation Army from January 2012 to April 2014. The serum ferritin (SF), red blood cell transfusion volume, hemoglobin and adverse drug reactions before and after treatment were observed. 

Results: A total of 8 MDS patients with secondary iron overload were taking Deferasirox (Deferasirox), including 7 males and 1 female, with a median age of 52 (38-71) years old. After 3 months of treatment, the efficacy was evaluated as complete response (CR) in 3 cases, minimal reaction (MiR) in 3 cases, and stable iron overload (SIL) in 2 cases. The overall response rate was 75.0% (6/8), and the median red blood cell transfusion volume was 2 (1-3) u/month. After 1 year of treatment, the efficacy was evaluated as CR in 5 cases, MiR in 2 cases, and SIL in 1 case. The overall response rate was 87.5% (7/8). 

Compared with before treatment, the patient's SF was significantly reduced [(871.0±584.2) vs (2164.9±1233.6) ng/ml] and hemoglobin was significantly increased [(101.5±34.59) vs (65.37±21.35) g/L] after 1 year of treatment, and the differences were statistically significant (P<0.05). After 1 year, 5 patients were weaned from blood transfusion, and the median red blood cell transfusion volumes of the remaining 3 patients were 0.5 u/month, 1.5 u/month, and 2.0 u/month respectively. After 1 year of treatment, only one patient died. There were 3 cases of nausea and vomiting and 1 case of diarrhea after taking the medicine. 

Conclusion: Deferasirox (Deferasirox) is safe and effective in the treatment of secondary iron overload in MDS.

Deferasirox is a tridentate iron chelator that combines with ferric iron ions in a 2:1 ratio to form a complex that is excreted in the feces, thereby reducing iron storage in the body. Because Deferasirox continues to exist in plasma, it can continuously reduce plasma non-transferrin-bound iron and directly remove iron formed from toxicity in the body.

The above is the content of (Enrig, Deferasirox) effects, I hope it can help you!